Clinical trial
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
NCT00091572 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00091572 |
|---|---|
| Title | Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) |
| Official title | Extended Schedule, Escalated Dose Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Collaborators | European Organisation for Research and Treatment of Cancer - EORTC |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Temozolomide, Dacarbazine |
| Enrollment | 859 |
| Start date | Oct 20, 2004 |
| Primary completion | Dec 31, 2007 |
| Completion | Dec 31, 2007 |
| First posted | Sep 14, 2004 |
| Last update posted | Jun 6, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: